Our Platforms

Optimize your chance to get the appropriate reimbursement in a specific country

Rely on solid data

Prismaccess provides comprehensive overviews and specific country regulations and guidelines on HTA and reimbursement.


PrismHEOR implements, harmonizes and translates published data in economic evaluation and outcome research, allowing HEOR departments to retrieve trends and insights.


Dedicated to market access, HEOR and pricing departments, our platforms cover 27 regulation agencies worldwide and 20 years of data on 1,000 therapeutic areas, allowing to anticipate market access positioning and rely on secure and exhaustive data.


  • User friendly visualization of key rationales and insights
  • Predictive understanding of emerging trends including those within clinical data packages
  • Essential prediction and analysis leading to a successful reimbursement
  • Focus on country specific processes and values

AI to gain power of insight

We are integrating AI and Machine learning to enhance the capabilities of our platforms.


Forecasts and screenings, accelerated search in hundreds of documents, real-time response to a given problem, extraction and analysis, our data will be processed with increased power.


The reimbursement policy of health authorities is becoming more restrictive with the increased number of innovative drugs introduced on the market.

With a fast process of large volumes of data, Prioritis is able to deliver deep analysis on specific criteria, essential for a successful assessment.


The key inputs managed by AI:

  • 20 years data collection worldwide
  • Clinical study design, endpoints and results
  • Health Technology Assessment decisions worldwide, including clinical, QoL, cost-effectiveness outcomes and PROs
  • Reimbursement and pricing data

High quality data for high valuable solutions

Prismaccess incorporates data on medicinal products from marketing authorization to price publications.

Our database covers all therapeutic areas from major HTA countries and is monitored and updated on a daily basis by our HTA experts.

  • Regulatory data: marketing authorization details including approved indications, approval dates, directly linked to payer decisions on driven HTA markets
  • Clinical data: comparators, endpoint acceptance, target populations
  • Economic data: pricing data at launch, treatment costs, ICERs etc.

Reimbursement & Pricing database

Access immediately to key information to incorporate into your product or disease area landscape.


  • A powerful tool to track and understand different HTA procedures
  • A comprehensive database of decisions from HTA and regulatory agencies
  • Detailed information on product recommendations, clinical and economic limitations
  • Official launch prices and price evolution


Search can be made by drug name, active ingredient, manufacturer, type of recommendation, therapeutic area. Our interface has been specifically built to facilitate downloads, data extraction and printing.


Raising consistency and reducing uncertainty

With PrismHEOR, Prioritis has extended its offering to include an overview of different decision-analytic assessments across multiple HTA markets.


  • Comprehensive outcome of discussions, decisions and limitations behind each economic evaluation
  • Intuitive search tool developed with a customized reliable IT
  • Powerful feature to create and customize reports
  • Accessible interface built to facilitate extraction of charts and figures
For more information, feel free to contact us